Huma Secures EU MDR Approval For Medtech Software That Can Be Used In Any Disease

Huma Therapeutics has secured the first ever EU regulatory approval for a “disease agnostic” class IIb medtech software platform. CEO Dan Vahdat tells Medtech Insight how the product can be configured to monitor patients with any condition.

Huma Therapeutics
• Source: Huma Therapeutics

UK-based Huma is the world’s first company to receive class IIb certification under the EU Medical Device Regulation for a disease agnostic Software as a Medical Device (SaMD) platform, it announced on 23 March. This certification means that the product can now be configured for use in any patient and for the management of any condition.

The monitoring platform, which was previously certified for use in the EU as a class I device in 2018 and used in a much more limited capacity, can be used...

More from Europe

More from Geography